Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE
· Real-Time Price · USD
6.84
-0.11 (-1.58%)
At close: Jun 16, 2025, 3:59 PM
-1.58% (1D)
| Bid | 6.78 |
| Market Cap | 1.05B |
| Revenue (ttm) | 104.94M |
| Net Income (ttm) | -112.33M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -9.12 |
| Forward PE | -6.57 |
| Analyst | Buy |
| Ask | 7.27 |
| Volume | 415,373 |
| Avg. Volume (20D) | 1,450,068 |
| Open | 6.99 |
| Previous Close | 6.95 |
| Day's Range | 6.78 - 6.99 |
| 52-Week Range | 4.25 - 16.74 |
| Beta | -1.05 |
Analyst Forecast
According to 0 analyst ratings, the average rating for WVE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-17.08%
Shares of vaccine and gene therapy stocks are trad...
Unlock content with
Pro Subscription
1 month ago
+7.47%
Wave Life Sciences shares are trading higher after Cantor Fitzgerald initiated coverage with an Overweight rating and $10 price target.
2 months ago · seekingalpha.com
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved i...
